Introduction: Dietary polyunsaturated fatty acids (PUFAs) have immunoregulatory
remain elusive. 3, 4 Early-life dietary exposure has been proposed as a key determinant of allergic disease outcomes. 3 Breast milk is the first dietary exposure for most newborns and contains many immunomodulatory substances, 5 including polyunsaturated fatty acids (PUFA). 6 PUFAs can be categorized as n-3 or n-6
PUFA based on the location of the first double bond. Counting from the methyl end of the carbon chain, in n-3 the first double bond is placed in the C-3 position for n-3 and the C-6 position for n-6. N-3
PUFA has the ability to reduce the production of anti-inflammatory substances. It also stabilizes T-cell membranes, which in turn reduces allergic inflammation. [7] [8] [9] In contrast, n-6 PUFA enhances the inflammatory response. 10 Based on these inflammatory properties, it has been hypothesized that colostrum and breast milk PUFA may influence the risk of allergic disease. Although a number of papers have been published on the relationship between colostrum and breast milk fatty acids and allergic disease outcomes, the evidence has not been systematically reviewed and synthesized.
Dietary intervention in early life to modify the levels of fatty acids has been proposed as a means of allergic disease prevention 11, 12 but the evidence from intervention trials is inconclusive. 13 The outcomes of intervention trials cannot be directly compared with the associations obtained from breast milk PUFA observational studies as the intervention doses are much larger than the normal biological doses.
The aim of this systematic review was to appraise all available literature on the relationship between colostrum/breast milk fatty acids and allergic disease outcomes. This may aid understanding of the impact of breast milk PUFA on the prevalence of allergic disease outcomes, and inform the design of future intervention trials.
2 | ME TH ODS
| Search strategy
Publications related to fatty acids in breast milk and allergic disease outcome were identified using Medline (PubMed) and EMBASE platforms. The last search was performed on 27th May 2016, and both key and MeSH terms were used (see online supplement for full search details). The key words used for the search were as follows:
(i) breast milk terms-"breast milk" "human milk" "colostrum"; (ii) fatty acid terms-"poly unsaturated fatty acids" "n-3" "n-6"; (iii) outcome terms-"allergic disease" "asthma" "wheeze" "sensitization" "allergic rhinitis" "eczema" and "lung function" (further details in online supplementary material). This review was prospectively registered in PROSPERO systematic review registry (No 2015023420).
| Inclusion and exclusion criteria
Only those studies that (i) reported original data; (ii) included a quantitative assessment of fatty acids in breast milk and/or colostrum;
and (iii) reported associations with at least one allergic disease, allergic sensitization or lung function outcome in the child were included in this review.
| Selection of articles
Title and abstract review was performed by two reviewers independently (NW and GB). If either reviewer considered the paper potentially eligible, both reviewers examined the full text for inclusion.
Any disagreements were resolved by involvement of a third reviewer (AL).
| Data extraction
Study design, sample size, details of the exposure categorization and outcomes measured were recorded. Details of available potential confounders, and the measures of association with allergic disease, were also extracted.
| Statistical analysis
Due to the heterogeneity of exposure classification between the included studies, it was not possible to undertake a meta-analysis.
Most common method of expressing the outcome was per weight percentage increase in individual fatty acid (w%-percentage of the individual fatty acid forms total fatty acids). However, results are presented in forest plots to visualize associations. The study name, the age at which the outcome was assessed and the family history of allergic diseases were included in the forest plots. Associations were grouped according to the type of fatty acid (n-3, n-6 and n-6/ n-3 ratio) in breast milk. STATA 13 was used for the analysis (version 13; Stata Corp, College Station, TX, USA).
Key Points
• It is proposed that allergic diseases are mediated via passive immunity as well as active immune-mediated pathways.
• Maternal nutrition status can modify the status of breast milk.
• Colostrum and breast milk PUFA may help to improve the immune function of the newborn.
• This systematic review of the published literature on the association between colostrum and breast milk fatty acids and allergic disease outcomes was unable to confirm that PUFA has beneficial effects on allergic disease outcomes.
• It is plausible that methodological issues have contributed to our results.
• Further research is needed using larger samples to clearly explore these associations.
| RESULTS
The Medline and EMBASE search identified 180 published papers.
After reviewing the titles and the abstracts, 39 papers were identified for the full-text review. From the 39 papers, 18 published papers met the inclusion criteria, from 15 unique study populations ( Figure 1 ). In addition to these, another paper was captured from journal alerts.
Therefore, this review contains 14 papers from 11 birth cohort studies, 7-9,14-24 with three of these cohorts (MACS, 7, 9 PIAMA 19, 20 and Swedish cohort 23, 24 ) generating two publications each. Two papers were from case-control studies 25, 26 and two were from cross-sectional studies. 27, 28 As some studies reported the same outcome at multiple time points in different publications, we summarized the results according to the study population (n = 15), rather than by publication (n = 18). This has resulted in instances where the number of citations exceeds the number of studies with a given result.
The sample sizes of the cohort studies ranged from 34 to 352 participants ( Table 1 ). All of the case-control and cross-sectional studies had less than 50 participants ( Table 1 ). The maximum age of follow-up was 14 years after birth for the cohort studies (Table 1) . 19 Only two studies assessed allergic disease outcomes beyond preschool age. 9, 19 Three studies measured PUFA levels in both colostrum and breast milk. 7, 9, 17, 23 Of the remaining studies, PUFA was measured either in colostrum 16, 22 or in breast milk. 8, 14, 15, 18, 19, 21, [25] [26] [27] [28] Gas chromatography was used in all of the studies to quantify fatty acids from colostrum and breast milk. The concentration of fatty acids was expressed as lipid based (% of lipids) for 16 studies, [7] [8] [9] 14, 16, [18] [19] [20] [22] [23] [24] [25] [26] [27] [28] while one reported results as wet-based technology (% of total weight). 17 Further details of the method used and how the individual fatty acids were expressed are given in Table S1 . While the concentrations of individual fatty acids were higher with the lipid-based analysis method compared to wet-based method, but the strength and direction of associations were similar. 17 Method of exposure categorization was also different among studies.
These included outcomes expressed as per weight%, 9, 19 per interquartile range (IQR) increase. 14, 18, 22 Some studies provided the mean 8, 16, 21 or median 25 fatty acid levels between affected and unaffected groups. Of the nine studies (ten publications) that reported the associations between total n-3 either in breast milk or in colostrum and eczema, only three found that increased levels of n-3 were associated with a decreased odds of eczema in childhood. 8, 18, 21 The remaining four studies found no association (Table 2/ Figure 2 ). 9, 15, 16, 19, 20, 22, 26 3.1.2 | N-6 and eczema
Of the eight studies (nine publications) that reported the association between total n-6 levels and eczema, one study observed increased 
| N-6/n-3 ratio and eczema
Of the five studies (six publications) that reported the association between the ratio of total n-6 to total n-3 and eczema, one found increased ratio increasing the risk of eczema 8 and the others did not find an association. Of the seven studies (eight publications) that reported the association between total n-3 and sensitization, 7, 8, 14, [17] [18] [19] [20] 22 three reported no association. 8, 19, 20 Four studies found that increased n-3 was associated with reduced risk of sensitization. 14, 17, 18, 22 From the three studies that assessed sensitization at the age of 1 year, two studies showed a reduced odds with increasing n-3 PUFA (highest vs lowest quartile OR 0.17 [95% CI: 0.04, 0.77] 18 and 0.14 [0.05, 0.39] 17 ). The third study found that the median value of n-3 in maternal milk of sensitized infants was lower than that found in nonsensitized (2.66 vs 2.88, P < .05). 22 From the two studies that assessed the outcome at 2 years, comparing the highest vs lowest quartile of n-3, in one study the association was not apparent (OR 0.89 [0.32,2.50]), 18 while the other showed nonsignificant trend towards a protective effect (0.49
14 In a high-risk birth cohort, Stoney et al 7 found that increased n-3 was associated with an increased risk of sensitization at both 6 and 24 months of age (Table 3/ Figure 3 ).
| N-6 and sensitization
Of the six studies (seven publications) that reported the total n-6 levels and sensitization, five reported no association. 7, 8, 14, 19, 22 T A B L E 1 (Continued) 
| N-6/n-3 ratio and sensitization
Of the four studies (five publications) that investigated the association between the n-6/n-3 ratio and sensitization, 7, 8, 20, 22, 26 only one 7 observed that an increased ratio was associated with decreased food sensitization. The other studies did not observe an association. Five studies (six publications) reported the association between total n-3 levels and wheeze or asthma. 9, [15] [16] [17] 19, 20 One cohort found that increased n-3 was associated with reduced risk of childhood asthma at both 4 and 14 years, 19, 20 with the protective effect at 14 years only among the children of mothers with allergy. 19 Two did not find any association between n-3 levels and asthma. 9, 17 Two studies reported the outcome of childhood wheezing, 15, 16 and neither found an association (Table 4 / Figure 4 ).
| N-6 asthma/wheeze
Of the five studies (six publications) that reported on n-6 levels and asthma or wheeze, two found an increased risk with increased levels of n-6 17,19 and three did not find any associations. Morales et al 16 assessed the association between n-6 and wheezing and found no effect between 7 and 14 months of age (OR 1.14, 95% CI: 0.57, 2.27).
| N-6/n-3 ratio and asthma/wheeze
Two studies (three publications) reported the association between the n-6/n-3 ratio and asthma. One found no association, 9 while the other found an association between increased ratio and reduced risk of asthma.
19,20
| Allergic rhinitis
Only one study 9 reported on allergic rhinitis. In this study, n-3 levels were not associated with allergic rhinitis ( 23 Up to the age of 12 months, 24 mean n-3 in breast milk was lower among the children with atopy compared to the nonatopic children (mean 1.5 and SD 0.3 and 1.8 and 0.5, respectively).
The ratio between n-6 and n-3 was high in breast milk of atopic children compared to the nonatopic children (6.9 AE 1.3 and 5.8 AE 1.2, respectively). By 18 months, there was no difference in PUFA concentration in colostrum according to the atopic status of the child, but differences were observed for specific subtypes of PUFA (C20:5 n-3
and C22:5 n-3) in breast milk at 1 and 3 months. At 1 month, C20:5 | 305 n-3 was higher among nonatopic children (0.07 AE 0.5 and 0.06 AE 0.03, P < .05) and the ratio between total n-6 and n-3 was lower among the atopic children (5.60 AE 1.3 and 6.40 AE 2.15, P < .05). In the 1-month breast milk samples, C22:5 n-3 was higher among the nonatopics (0.16 AE 0.08 and 0.12 AE 0.04, P < .05) and the ratio was lower among atopic children (5.80 AE 1.2 and 6.80 AE 1.4, P < .01).
Kankaapaa et al also reported the outcome as the child's atopic status (eczema or food allergy in the context of a positive SPT) and found that the n-6/n-3 ratio in 3-month breast milk samples was significantly higher among atopic children compared to healthy children (P < .05). 28 Businco et al reported on the associations between mature breast milk PUFA (2-8.8 months) and eczema (atopic dermatitis), but did not present results for total n-3, n-6 or their ratio.
This study identified that two n-6 fatty acids (20:3n-6 and 22:4 n-6)
were significantly lower in the breast milk of mothers of children with eczema, while one n-3 (22:6 n-3) was lower in the breast milk of mothers of children without eczema. 27 Laitinen et al 25 reported
eczema and sensitization as a combined outcome in a small sample of children (n = 31), and found that none of the breast milk PUFAs were associated with this outcome.
| DISCUSSION
A number of studies have investigated the association of colostrum or breast milk fatty acids and allergic disease outcomes with mixed results and no clear evidence of an association. Given the relatively small sample sizes of many of the studies included, and the associated imprecision of effect estimates, it would have been beneficial to pool results to obtain a combined estimate. However due to substantial differences in the reporting of exposures, we were unable to pool results to perform a meta-analysis.
This paper identified several key strengths and limitations in the available literature. While all the studies included in this review quantitatively assessed PUFA levels, the timing of breast milk sample collection varied from colostrum 16, 22 through to mature breast milk 26, 27 collected when the infant was up to 6 months old. While it is plausible that the timing of collection of breast milk (particularly colostrum vs mature milk) may impact on the associations between PUFA and allergic disease outcomes, few studies have reported the associations with allergic disease outcomes with breast milk PUFA collected at multiple times [7] [8] [9] 23, 24 and these studies have produced conflicting evidence. Further studies that compare associations with PUFA from breast milk collected at different times and allergy outcomes are required. Although a wide range of allergic disease outcomes were assessed in these studies, there were differences in the definitions used between the papers, and some outcomes were rarely reported. For example, only two studies 9, 19 assessed asthma as an outcome (which has the highest burden for all the allergic diseases) and three [15] [16] [17] reported associations with wheeze.
The exposure categorization varied across the studies, which prevented us pooling effect estimates. Some studies expressed outcomes as per weight percentage increase, 7, 9, 19, 20 and some studies expressed outcomes as per interquartile range (IQR). 14, 18 A number of studies expressed the results as mean 8, 16, 21 or median 22 fatty acid levels between the affected and unaffected groups, while other reported relative risk estimates (ORs or RRs) for the clinical outcomes per unit increase in fatty acid level. In addition, the majority of studies assessed fatty acid levels in a relatively small number of participants, limiting the statistical power to detect associations.
There are a range of potential biases that may have influenced the results of this review. As breastfeeding is an important public health issue, it is possible that some studies with negative findings might not have been published. This would result in publication bias and an overestimate of the beneficial effect of breast milk PUFA. The original paper reported n-6/n-3 ratio. However, given the high proportion of studies of breast milk PUFA which have observed null results, it seems unlikely that strong publication bias is present in this literature.
How potential confounding was dealt with was highly variable between the studies included in this review. A number of publications did not adjust for potential confounding factors at all, 21, 22, 24, 27, 28 leaving them at high risk of potential residual confounding. In contrast, other studies appear to have possibly overadjusted these associations [18] [19] [20] by including factors that occur after the exposure of breast milk PUFA, such as children's BMI 19 or respiratory tract infections in infancy. 17 These postbreastfeeding variables are more likely to be mediating factors (pathways via which breast milk PUFA influences allergic disease outcomes), rather than confounding factors. Adjusting for such mediating factors could result in underestimation of the effect of breast milk PUFA on these outcomes. None of the included studies that detected associations formally investigated potential mediators for these associations.
The published randomized controlled trials on early-life PUFA supplementation and childhood allergic disease and the observed effects are inconsistent. Two studies showed a risk reduction in allergic disease with n-3 supplementation, 29, 30 while the other trial 31 found no benefit. While inconclusive at this time, there seems to be some limited evidence that maternal supplementation with PUFA may be protective against allergic disease in the child. In contrast, the results of our systematic review based on naturally occurring colostrum and breast milk PUFA did not demonstrate any clear associations. The evidence based on PUFA supplementation trials to pregnant and lactating mothers is not directly comparable to the results reported in the observational studies summarized in this review, as the supplemented dose is far greater than the biological dose that can be obtained from a normal diet. 32 Furthermore, there are a number of factors that influence the transfer of maternal dietary supplementation with PUFA into breast milk. 32 For example, fatty acid desaturase enzyme level in mammary glands is a rate-limiting step in the metabolism of PUFA pathway. 33 These factors may create a disconnect between associations between maternal intake of PUFA and measured breast milk PUFA, and the associations with outcomes in the child.
In conclusion, we observed a few associations between levels of PUFAs in breast milk and allergic disease outcomes, and these associations were relatively inconsistent. Therefore, based on this review, there is currently insufficient evidence to warrant modifying the dietary exposures to PUFA to influence the colostrum or breast milk fatty acids as a preventive strategy for later childhood allergic disease outcomes. 
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